samedan logo
 
 
 
spacer
home > pmps > autumn 2019 > preparing for change
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Preparing for Change




The pharmaceutical packaging industry has evolved significantly in recent years as new technologies and pioneering solutions have been developed to meet changing market requirements. Additionally, companies continue to explore ways to drive efficiencies across the supply chain, streamline their operations, and reduce time to market.

Serialisation

Over the last few years we have seen the implementation of serialisation regulations within the pharma industry, in response to the number of counterfeit products entering the supply chain. These new regulations that now exist in multiple markets aim to combat this issue by making drug products verifiable as they pass through the supply chain, ensuring greater safety for patients.

In February 2019, regulators implemented the EU Falsified Medicines Directive (FMD). The regulation introduced new requirements for manufacturers whereby they are now expected to ensure products are affixed with a unique serial number and barcode. This guarantees each product’s shelf life, batch number, and origin are traceable and that products can be verified as legitimate at the point of dispense to the patient.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Dexter Tjoa is Director of Corporate Strategy at Tjoapack. He is responsible for devising, implementing, and evaluating the mid to long-term strategies of the company and the services it offers, as well as overseeing the commercial, finance, and IT departments within Tjoapack. Dexter has been with the company for three years, during which time he launched Meditraq, one of Tjoapack’s sister brands, which offers contract serialisation services. He holds a BSc in Mathematics from the University of London, UK, and an MSc in Mathematics and Computer Science from the University of Oxford, UK, and has previously worked in the technology sector.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement